---
document_datetime: 2025-07-23 18:11:01
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/apixaban-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: apixaban-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.3123836
conversion_datetime: 2025-12-28 04:18:20.504096
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Apixaban Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 21/07/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000269318                     | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z - to update Risk Management Plan of Apixaban Accord in line with the EPAR for Risk Management Plan of reference product Eliquis (V. 21.3) published on EMA website on 19-Aug-2024.                                                                                                                                                                                                                                                                                                                                                      |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000275536 | This was an application for a group of variations. C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted | 16/06/2025 | 18/07/2025 | SmPC, Annex II, Labelling and PL | Extension of indication to include the treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age for Eliquis (all strengths), As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 4.9, 5.1 and 5.2 of the SmPCs are updated. The Package Leaflet and Annex II are updated in accordance. The changes follow assessment of the same changes to the reference product Eliquis (EMEA/H/C/002148/X/0089). To update section 4.8 of the SmPC and section 4 of the PL with information on Anticoagulant-related nephropathy, following assessment of the same change to the reference product Eliquis (EMEA/H/C/PSUSA/00000226/202405). To include a single Patient Alert Card (PAC) combining already approved information for paediatric and adult patients in all boxes, and to update sections 4.2, 4.8(for 5 mg) and 5.2 of the SmPC and section 2 (for 5mg) of the PL to align with editorial changes |

<div style=\"page-break-after: always\"></div>

| made to the PI of the reference product. The changes follow assessment of the same changes to the reference product Eliquis (EMEA/H/C/002148/IB/0096)   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                          | Anticoagulant-related nephropathy, following assessment of the same change to the reference product Eliquis (EMEA/H/C/PSUSA/00000226/202405). C.I.2.a - To include a single Patient Alert Card (PAC) combining already approved information for paediatric and adult patients in all boxes, and to update sections 4.2, 4.8(for 5 mg) and 5.2 of the SmPC and section 2 (for 5mg) of the PL to align with editorial changes made to the PI of the reference product. The changes follow assessment of the same changes to the reference product Eliquis (EMEA/H/C/002148/IB/0096) Additionally, the MAH took the opportunity to update section 4.2, 4.9 and 5.1 of the SmPC and sections 3 and 4 of the PL with editorial changes to align with the PI of the reference product, and updated the contact information of the local representative for   |            |            |                 |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| Variation type IA / EMA/VR/0000248163    | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 03/02/2025 | N/A        |                 |
| Variation type IA_IN / EMA/VR/0000246186 | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 23/01/2025 | 18/07/2025 | Annex II and PL |

<div style=\"page-break-after: always\"></div>

| B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.2 Including batch control/testing - Accepted   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|